Prescription medicine
Baxdrostat Brand names: Baxfendy
Baxdrostat (Baxfendy) is a prescription medicine with an FDA approval on record since 2026. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the baxdrostat FDA label on DailyMed (effective August 7, 2026, AstraZeneca Pharmaceuticals LP); the NDA 219878 record on Drugs@FDA; every baxdrostat label on DailyMed.
Highlights of the record
FDA label of August 7, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageBAXFENDY, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure in adults who are not adequately controlled on other agents.
Forms and strengths
- 1 mg
- 2 mg
Film-coated tablet.
On the market
- Earliest approval on file
- May 15, 2026 Baxfendy, Astrazeneca Ab; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- February 4, 2033 Baxfendy tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is baxdrostat used for?
From the label: indications and usageBAXFENDY, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure in adults who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction of these events with BAXFENDY. […]
Conditions named in the indications of baxdrostat's FDA labels, with every medicine labeled for each:
Source: FDA drug label (BAXFENDY), AstraZeneca Pharmaceuticals LP, effective August 7, 2026 (SPL set b1fc1ee7-facc-4099-b3db-a4c1daeaa4be), via openFDA; the full label on DailyMed
Is there a generic for baxdrostat (Baxfendy)?
No generic baxdrostat is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 1 patent for Baxfendy tablets: the compound patent runs to February 4, 2033. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2026 earliest approval on file
- 2033 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What else is labeled for the same conditions as baxdrostat?
72 other medicines are given the same way (oral) and in the same FDA class as baxdrostat or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Metoprolol | High blood pressure | 64 labelers | $0.085 per tablet 100 mg tablet | A presentation being discontinued |
| Diltiazem | High blood pressure | 42 labelers | $0.144 per capsule 24h ER(cd) 120 mg capsule | A presentation being discontinued |
| Lisinopril | High blood pressure | 36 labelers | $0.0254 per tablet 20 mg tablet | No current entry |
| Propranolol | High blood pressure | 38 labelers | $0.0493 per tablet 20 mg tablet | In shortage |
| Losartan | High blood pressure | 44 labelers | $0.0327 per tablet 50 mg tablet | No current entry |
| Amlodipine | High blood pressure | 42 labelers | $0.0102 per tablet 5 mg tablet | No current entry |
| Clonidine | High blood pressure | 37 labelers | $0.0241 per tablet 0.1 mg tablet | No current entry |
| Valsartan | High blood pressure | 34 labelers | $0.0963 per tablet 40 mg tablet | A presentation being discontinued |
Every medicine labeled for the same conditions as baxdrostat
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to baxdrostat
- 72 medicines for the same use
- Check an interaction
- what two or more labels say about each other